Research advances in the early predictive factors for non-neoplastic portal vein thrombosis in liver cirrhosis

Zunlan ZHOU; Lina YANG; Qingqing LI; Hong WANG

doi:10.3969/j.issn.1001-5256.2022.09.039

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2150-2154

PDF( 1966 KB)

Research advances in the early predictive factors for non-neoplastic portal vein thrombosis in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.09.039

Zunlan ZHOU^{1, 2},
Lina YANG¹,
Qingqing LI¹,
Hong WANG^{1
,
,
,}

1.
Department of Gastroenterology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, China
2.
Department of Gastroenterology, Guizhou Aerospace Hospital, Zunyi, Guizhou 563000, China

More Information

Corresponding author: WANG Hong, wanghong89zy@163.com(ORCID: 0000-0001-5411-3041)
Received Date: 2022-01-07
Accepted Date: 2022-02-25
Published Date: 2022-09-20

Abstract

Abstract

Portal vein thrombosis (PVT) is one of the common complications in patients with decompensated liver cirrhosis, including non-neoplastic PVT and portal vein tumor thrombus after the onset of primary liver cancer. It can lead to the deterioration of liver function, aggravate the portal hypertension-related adverse events including esophagogastric variceal bleeding, reduce the survival rate of patients after liver transplantation, and even threaten the life of patients in severe cases. Therefore, it is of great clinical significance to further explore the risk factors and early predictive factors for PVT. This article elaborates on the recent advances in the early predictive factors for non-neoplastic PVT in liver cirrhosis from the aspects of the three elements of thrombosis, the severity of liver injury, and the endoscopic treatment of esophagogastric varices. The analysis of related research shows that some early predictive factors are clearly associated with the formation of PVT, which provides help for the early identification of PVT; however, specific predictive values may be unclear or have certain differences, which needs to be confirmed by multicenter prospective studies.
- Liver Cirrhosis,
- Venous Thrombosis,
- Risk Factors

FullText(HTML)

References(42)

References

[1]	BHANGUI P, LIM C, LEVESQUE E, et al. Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation[J]. J Hepatol, 2019, 71(5): 1038-1050. DOI: 10.1016/j.jhep.2019.08.012.
[2]	TURON F, DRIEVER EG, BAIGES A, et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors[J]. J Hepatol, 2021, 75(6): 1367-1376. DOI: 10.1016/j.jhep.2021.07.020.
[3]	FRANCOZ C, VALLA D, DURAND F. Portal vein thrombosis, cirrhosis, and liver transplantation[J]. J Hepatol, 2012, 57(1): 203-212. DOI: 10.1016/j.jhep.2011.12.034.
[4]	TAO YF, TENG F, WANG ZX, et al. Liver transplant recipients with portal vein thrombosis: a single center retrospective study[J]. Hepatobiliary Pancreat Dis Int, 2009, 8(1): 34-39. http://www.hbpdint.com/CN/article/downloadArticleFile.do?attachType=PDF&id=3109
[5]	DONG G, HUANG X, JIANG S, et al. Simvastatin mitigates apoptosis and transforming growth factor-beta upregulation in stretch-induced endothelial cells[J]. Oxid Med Cell Longev, 2019, 2019: 6026051. DOI: 10.1155/2019/6026051.
[6]	ZOCCO MA, DI STASIO E, DE CRISTOFARO R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development[J]. J Hepatol, 2009, 51(4): 682-689. DOI: 10.1016/j.jhep.2009.03.013.
[7]	STINE JG, WANG J, SHAH PM, et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study[J]. Liver Int, 2018, 38(1): 94-101. DOI: 10.1111/liv.13500.
[8]	MARUYAMA H, OKUGAWA H, TAKAHASHI M, et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes[J]. Am J Gastroenterol, 2013, 108(4): 568-574. DOI: 10.1038/ajg.2012.452.
[9]	DONG G, HUANG XQ, ZHU YL, et al. Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis[J]. Ann Transl Med, 2021, 9(4): 289. DOI: 10.21037/atm-20-4912.
[10]	ZHANG Y, WEN TF, YAN LN, et al. Preoperative predictors of portal vein thrombosis after splenectomy with periesophagogastric devascularization[J]. World J Gastroenterol, 2012, 18(15): 1834-1839. DOI: 10.3748/wjg.v18.i15.1834.
[11]	HUANG L, YU Q, PENG H. Hemorheological alteration in patients with cirrhosis clinically diagnosed with portal vein system thrombosis after splenectomy[J]. Med Sci Monit, 2021, 27: e931157. DOI: 10.12659/MSM.931157.
[12]	AUSTIN SK, LAMBERT JR. The JAK2 V617F mutation and thrombosis[J]. Br J Haematol, 2008, 143(3): 307-320. DOI: 10.1111/j.1365-2141.2008.07258.x.
[13]	RABIE H, OTHMAN W, ELSABAAWY DM, et al. Janus Kinase-2 mutation associated portal vein thrombosis complicating liver cirrhosis and hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2021, 22(1): 267-275. DOI: 10.31557/APJCP.2021.22.1.267.
[14]	GAMEIRO AF, ROBALO NUNES A, GUERRA P, et al. Portal vein thrombosis secondary to occult polycythemia vera[J]. Eur J Case Rep Intern Med, 2020, 7(12): 002003. DOI: 10.12890/2020_002003.
[15]	SAUGEL B, LEE M, FEICHTINGER S, et al. Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis[J]. J Thromb Thrombolysis, 2015, 40(1): 54-60. DOI: 10.1007/s11239-014-1124-z.
[16]	AMITRANO L, BRANCACCIO V, GUARDASCIONE MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis[J]. Hepatology, 2000, 31(2): 345-348. DOI: 10.1002/hep.510310213.
[17]	XIONG JP, PENG YY, ZHANG YX. Differential protein screening in patients with liver cirrhosis complicated with portal vein thrombosis [J]. J Clin Hepatol, 2018, 34(1): 112-117. DOI: 10.3969/j.issn.1001-5256.2018.01.023. 熊静平, 彭媛媛, 张跃新. 肝硬化合并门静脉血栓患者的差异蛋白筛选[J]. 临床肝胆病杂志, 2018, 34(1): 112-117. DOI: 10.3969/j.issn.1001-5256.2018.01.023.
[18]	QUECK A, CARNEVALE R, USCHNER FE, et al. Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS[J]. Gut, 2020, 69(8): 1535-1536. DOI: 10.1136/gutjnl-2019-319044.
[19]	MEI B, ZHENG K, CHEN XP. The relationship between portal vein thrombosis and platelet membrane protein CD62P after devascularization[J]. Acta Med Univ Sci Technol Huazhong, 2006, 35(4): 548-549, 552. DOI: 10.3870/j.issn.1672-0741.2006.04.037. 梅斌, 郑凯, 陈孝平. 断流术后门静脉血栓形成与血小板膜蛋白CD62P的关系[J]. 华中科技大学学报(医学版), 2006, 35(4): 548-549, 552. DOI: 10.3870/j.issn.1672-0741.2006.04.037.
[20]	LIN WY, LU X, FAN FJ, et al. Predictive effect of mean platelet volume in patients with portal vein thrombosis: a Meta-analysis of case-control studies[J]. Curr Med Sci, 2018, 38(4): 575-581. DOI: 10.1007/s11596-018-1916-z.
[21]	FIMOGNARI FL, de SANTIS A, PICCHERI C, et al. Evaluation of D-dimer and factor Ⅷ in cirrhotic patients with asymptomatic portal venous thrombosis[J]. J Lab Clin Med, 2005, 146(4): 238-243. DOI: 10.1016/j.lab.2005.06.003.
[22]	WEI Y, CHEN X, SHEN H, et al. P-selectin level at first and third day after portal hypertensive splenectomy for early prediction of portal vein thrombosis in patients with cirrhosis[J]. Clin Appl Thromb Hemost, 2018, 24(9_suppl): 76S-83S. DOI: 10.1177/1076029618788180.
[23]	FEI Y, ZONG GQ, CHEN J, et al. Evaluation of the value of D-dimer, P-selectin, and platelet count for prediction of portal vein thrombosis after devascularization[J]. Clin Appl Thromb Hemost, 2016, 22(5): 471-475. DOI: 10.1177/1076029615569273.
[24]	LIU RH, LIAN HL. Early predictive value of P-selectin and D-dimer for portal vein thrombosis in cirrhosis[J]. Chin J Thromb Hemost, 2021, 27(6): 974-976. DOI: 10.3969/j.issn.1009-6213.2021.06.031. 刘瑞红, 廉恒丽. P-选择素和D二聚体对肝硬化门静脉血栓形成的早期预测价值[J]. 血栓与止血学, 2021, 27(6): 974-976. DOI: 10.3969/j.issn.1009-6213.2021.06.031.
[25]	ZHANG D, HAO J, YANG N. Protein C and D-dimer are related to portal vein thrombosis in patients with liver cirrhosis[J]. J Gastroenterol Hepatol, 2010, 25(1): 116-121. DOI: 10.1111/j.1440-1746.2009.05921.x.
[26]	VIOLI F, FERRO D, BASILI S, et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients[J]. Thromb Haemost, 1997, 77(1): 44-47. DOI: 10.1055/s-0038-1655904
[27]	YAO YH, LUO Y, ZHU JL, et al. Measurement and clinical significance of peripheral blood vascular endothelial growth factor in patients with liver cirrhosis and portal vein thrombosis[J]. J Clin Hepatol, 2020, 36(9): 1966-1969. DOI: 10.3969/j.issn.1001-5256.2020.09.011. 姚运海, 罗艳, 朱京乐, 等. 肝硬化合并门静脉血栓患者外周血血管内皮生长因子的检测及意义[J]. 临床肝胆病杂志, 2020, 36(9): 1966-1969. DOI: 10.3969/j.issn.1001-5256.2020.09.011.
[28]	SAMANT H, ASAFO-AGYEI KO, GARFIELD K. Portal vein thrombosis[M]. Treasure Island (FL): StatPearls Publishing, 2021.
[29]	HAN JB, SHU QH, ZHANG YF, et al. Predictive value of inflammation biomarkers in patients with portal vein thrombosis[J]. J Clin Transl Hepatol, 2021, 9(3): 384-391. DOI: 10.14218/JCTH.2020.00159.
[30]	PRAKTIKNJO M, TREBICKA J, CARNEVALE R, et al. Von willebrand and factor Ⅷ portosystemic circulation gradient in cirrhosis: implications for portal vein thrombosis[J]. Clin Transl Gastroenterol, 2020, 11(2): e00123. DOI: 10.14309/ctg.0000000000000123.
[31]	NERY F, CARNEIRO P, CORREIA S, et al. Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study[J]. Eur J Gastroenterol Hepatol, 2021, 33(Suppl 1): e108-e113. DOI: 10.1097/MEG.0000000000001982.
[32]	HUANG X, FAN X, ZHANG R, et al. Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices[J]. Eur J Gastroenterol Hepatol, 2020, 32(3): 401-405. DOI: 10.1097/MEG.0000000000001526.
[33]	SONZOGNI A, PREVITALI G, SEGHEZZI M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations[J]. Liver Int, 2020, 40(9): 2110-2116. DOI: 10.1111/liv.14601.
[34]	KHEYRANDISH S, RASTGAR A, ARAB-ZOZANI M, et al. Portal vein thrombosis might develop by COVID-19 infection or vaccination: a systematic review of case-report studies[J]. Front Med (Lausanne), 2021, 8: 794599. DOI: 10.3389/fmed.2021.794599.
[35]	DÍAZ LA, IDALSOAGA F, CANNISTRA M, et al. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data[J]. World J Gastroenterol, 2020, 26(48): 7693-7706. DOI: 10.3748/wjg.v26.i48.7693.
[36]	LI L, LU SX, CUI CX, et al. Analysis of risk factors for portal vein thrombosis in 591 patients with liver cirrhosis[J]. Fudan Univ J Med Sci, 2017, 44(3): 288-293. DOI: 10.3969/j.issn.1672-8467.2017.03.006. 李玲, 陆申新, 崔春晓, 等. 591例肝硬化患者门静脉血栓形成的危险因素分析[J]. 复旦学报(医学版), 2017, 44(3): 288-293. DOI: 10.3969/j.issn.1672-8467.2017.03.006.
[37]	MALINCHOC M, KAMATH PS, GORDON FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871. DOI: 10.1053/he.2000.5852.
[38]	GÎRLEANU I, TRIFAN A, COJOCARIU C, et al. The risk of thrombotic events in patients with liver cirrhosis[J]. Rev Med Chir Soc Med Nat Iasi, 2012, 116(4): 991-996. http://www.revmedchir.ro/uploads/1/5/7/2/15722076/8_c_31_girleanu_i_mip_ao_991-996.pdf
[39]	LIU YZ, SUN YN, LI P, et al. Study of influence factors the prognosis of esophageal variceal sclerosis in patients with cirrhosis[J]. Chin Med Herald, 2021, 18(22): 109-112. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202122025.htm 刘远志, 孙亚男, 李鹏, 等. 肝硬化患者食管静脉曲张硬化治疗术预后的影响因素研究[J]. 中国医药导报, 2021, 18(22): 109-112. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202122025.htm
[40]	LI LJ, WANG S, WEN ZF, et al. Analysis of risk factors for portal vein thrombosis after gastric varices tissue adhesive injection[J]. J Sun Yat-Sen Univ(Medical Sciences), 2015, 36(6): 936-942. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2015.0153. 李雷佳, 王省, 文卓夫, 等. 胃底静脉曲张组织黏合剂注射术后门静脉血栓形成的危险因素分析[J]. 中山大学学报(医学科学版), 2015, 36(6): 936-942. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2015.0153.
[41]	SHEN DJ, QIAN XX, WANG J, et al. Analysis of risk factors for postoperative non-acute symptomatic portal vein thrombosis after endoscopic gastric varices injection [J]. J Chin Physician, 2021, 23(3): 338-342. DOI: 10.3760/cma.j.cn431274-20210129-00140. 沈丹杰, 钱孝先, 王剑, 等. 内镜下胃底静脉曲张注射治疗术后非急性症状性门静脉血栓形成的危险因素分析[J]. 中国医师杂志, 2021, 23(3): 338-342. DOI: 10.3760/cma.j.cn431274-20210129-00140.
[42]	GABALLA D, BEZINOVER D, KADRY Z, et al. Development of a model to predict portal vein thrombosis in liver transplant candidates: the portal vein thrombosis risk index[J]. Liver Transpl, 2019, 25(12): 1747-1755. DOI: 10.1002/lt.25630.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (311) PDF downloads(34)

Research advances in the early predictive factors for non-neoplastic portal vein thrombosis in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.09.039

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in the early predictive factors for non-neoplastic portal vein thrombosis in liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.09.039

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content